Introduction
Of all the autoimmune diseases, none has been as popular a target of cell and gene-based prophylactic and therapeutic interventions as type I diabetes mellitus. The delineation of the cellular effectors and the molecular pathways involved in the breakdown of central and peripheral tolerance has promoted interventions as diverse as bone marrow transplantation with or without antibody-based immunosuppression for tolerance induction, transplantation of genetically engineered islets of Langerhans to restore insulin production, embryonic and pancreatic stem cells and non pancreatic progenitors as surrogate b cells. Almost all of these strategies have been realized in the non obese diabetic (NOD) mouse model, the workhorse of this area of investigation and, in parallel, yet to a smaller degree pursued in the diabetesprone BioBreeding (DP-BB) rat. It is worth noting that many of these strategies have successfully prevented diabetes with varying effects on the degree of insulitis (the cellular inflammation in and around the islets) as outlined by Atkinson and Leiter. 1 in a very notable list. In humans, to date, the only clinically acceptable treatment for type I diabetes, other than insulin replacement, remains islet transplantation under the cover of pharmacologic immunosuppression. A very recent safety trial has begun using an anti-CD3 antibody, but the results require confirmation and further safety analysis. Whether the cell-and gene-based strategies published in the last decade will ever be clinically translatable is not yet clear. We undertook to review these strategies and their potential clinical utility with the ultimate objective of giving a perspective on the field from the view of gene therapy.
Type I diabetes mellitus: the autoimmune process
There is no doubt that type I diabetes mellitus (TIDM) is genetically determined and is triggered by an as-yet unidentified postnatal determinant, very likely environmental in nature. The genetics of the disease is multifactorial and involve two loci (IDDM1 and IDDM2) confirmed to be in linkage with the disease. IDDM1 encompasses the HLA gene complex and it alone defines the most important risk factor. In humans, the disease is associated with the inheritance of DR3/DR4 haplotypes (DR3: DQA1*0501, DQB1*0201 and DR4: DQA1*0301, DQB1*0302). 2, 3 IDDM2 has been mapped to a variable number of tandem repeats (VNTR) polymorphism upstream of the insulin gene promoter, which can determine thymic levels of insulin. 4, 5 In fact, a recent study demonstrated that the number of active copies of insulin in a transgenic mouse can influence the degree of immune cell reactivity towards insulin, a putative autoantigen. 6 A number of other loci have demonstrated suggestive associations, but to date, none of these results have been replicated to establish significant linkage with the disease. [7] [8] [9] A number of earlier hypotheses with some supporting evidence have been put forward to explain the possible mechanism of action of the environmental trigger including b-cell death secondary to virally triggered inflammation, molecular mimicry, superantigens and diet. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] What is certain is that at some point postnatally, the immune system of a genetically predisposed individual is activated to infiltrate chronically the islets of Langerhans. While the initial phase of infiltration may not involve b-cell destruction, a number of studies in vivo and in vitro suggest that immune cells become able to render b-cells dysfunctional through the actions of cytokines they produce such as interleukin-1b. Figure 1 illustrates what many believe to be the course of islet inflammation. Many lines of evidence indicate that antigen-presenting cells (APC), especially dendritic cells (DC) are pathologically activated to orchestrate the insulitic process. 24 It is thought that islet-resident APC respond to a microenvironmental anomaly (perhaps bcell death and/or impaired b-cell turnover or apoptosis [25] [26] [27] ) and initiate the insulitis process by migrating out of the islets and into the peripheral pancreatic lymph nodes. By presenting the b-cell antigens they have acquired, the APC interact with b-cell-reactive T cells, which escaped thymic deletion and trigger their activation and proliferation ( Figure 1 ). Once activated, these T cells act as one pole of a chronic tug-of-war between bcell-specific autoimmunity and peripheral mechanisms of tissue-specific tolerance. Regulatory T cells of various cell surface phenotypes and cytokine secretion profiles may also be involved in modulating this unstable equilibrium. Ultimately, this chronic process ends in favor of the b-cell-reactive T cells, which eventually end up destroying enough b-cell mass to render the patient insulin-dependent. This process has been extensively studied in the NOD mouse and is believed to occur in humans as well.
Lessons to be learned: gene vectors or cells or both?
An appreciable amount of work has focused on using viral vectors to infect intact islets in culture prior to transplantation into recipients to impede the allogeneic rejection (reviewed in Giannoukakis et al 28, 29 ). The excitement generated by these studies, however, was tempered by the appreciation that permanent allograft survival was generally not achieved. Often, to explain this limited success, investigators invoke the immunogenicity of the particular vector used, although recent evidence suggests that the quality of the islets may be more crucial than the vector choice in determining the presence and grade of inflammation in and around the graft. 30 Table 1aa lists the vectors that have been used to date to transduce intact human islets as well as their pros and cons (Table 1c) . (Table 1b lists their properties). The list indirectly demonstrates that no 'ideal' vector yet exists. New technology, including small interference RNA (siRNA), 31 adeno-associated virus inverted terminal repeat (AAV ITR)-based plasmids, 32, 33 novel classes of lentivirus (equine infectious anemia virus-EIAV; feline immunodeficiency virus-FIV), [34] [35] [36] [37] [38] [39] [40] lentivirus-herpesvirus hybrids and other viral vectors is in development, but their efficiency has yet to be reported in the context of Figure 1 Multistep process of insulitis. During ontogeny, a population of thymocytes whose TCR recognize b-cell-specific antigens are either not deleted in the thymus, or fail to be tolerized subsequently, in the periphery. These T cells may circulate dormant, or may be active, but suppressed by regulatory T-cell networks. Islet-resident APC (DC or macrophages) are normally in a steady-state flux sampling the microenvironment. An as-yet unidentified microenvironmental anomaly shifts their phenotype into activators of an inflammatory response, as they migrate out of the islet environment and into the peripheral lymphoid organs. There, they eventually encounter the autoreactive T cells. In the meantime, antigen nonspecific inflammation progresses within islets because of macrophage and DC secretion of soluble mediators of b-cell dysfunction and apoptosis activation. Herpes simplex virus 233, 234 Cationic liposomes 204, 205, 214 Peptide fusion domains 118, 235 Therapeutics for type I diabetes mellitus R Bottino et al intact islet transduction. Equally unknown is the degree to which these vectors can contribute to post-transplantation inflammation. Cell therapy constitutes an alternative approach to induce tolerance to alloantigens. Allogeneic bone marrow transplantation, with or without the addition of immunoregulatory antibodies (blocking CD28:B7 and CD40:CD40 ligand interactions), has been the choice of many investigators to promote allogeneic islet transplantation in mouse models of autoimmune diabetes. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] In some instances, permanent allograft survival has been reported in prediabetic mice (permanent in the sense that the recipient maintained normoglycemia at the time it was last tested). It is not clear, however, if these strategies would work equally well in an already-diabetic individual. A number of studies attempted to promote the activity of regulatory immune cells by DC. This novel and rational approach, however, may require multiple administrations to maintain a sufficient level of activity. 51, 52 Combinations of these approaches, including gene-engineered DC expressing a variety of immunosuppressive molecules, have shown promise in allograft survival. [53] [54] [55] [56] [57] [58] [59] and are awaiting rigorous testing in the context of islet allograft transplantation. Considering successes and failures, it is perhaps fair to conclude that while gene vectors and cells alone may not have yet supported permanent islet allograft survival, their utility cannot be yet dismissed as many important parameters have still to be evaluated, including combinative approaches. In fact, very few studies have attempted to engineer islets expressing more than one immunoregulatory transgene at a time. This is an important aspect of the problem to consider since the immune response against the transplant (and perhaps the vector) may involve more than one pathway.
A General overview of strategies: prevention versus insulin replacement
Other than insulin replacement by daily injections of the hormone, the only other clinically acceptable means of insulin restoration remains islet transplantation. [60] [61] [62] [63] Recent advances in understanding transplantation immunology in general and the process of insulitis and the molecular/genetic bases of failure of central and/or New data suggest that a critical period between time of diagnosis and actual destruction of b-cell mass required for appropriate glycemic control (the so-called 'honeymoon period'; see below) may be exploited immunologically to obviate the need of islet transplantation altogether. While antibody-based approaches are currently being tested, it is anticipated that emerging gene and cell therapies can overcome the safety and negative systemic effects associated with the antibody approach.
Prevention strategies
In order to prevent the disorder, one must be able to identify first with a sufficient degree of confidence individuals who are at very high risk for developing type I diabetes. While inheritance of susceptibility alleles at loci linked to and/or associated with the disorder is an important risk factor, it alone cannot guarantee that the individual will in fact become diabetic. This is the main reason for the ongoing debates on prevention based on genetic screening. 2, 64 While outright prevention based only on genetic screening may not be yet acceptable, other strategies that fall inside the realm of 'prevention' can be acceptable. There are data indicating that newly onset diabetics still possess adequate b-cell mass to sustain normoglycemia if the autoimmune inflammation can be promptly controlled. [65] [66] [67] [68] [69] [70] [71] The time between diagnosis and elimination of b-cell mass adequate to sustain normoglycemia has been termed the 'honeymoon' period. One can exploit immunoregulatory networks to promote hyporesponsiveness of autoaggressive immune cells in this period as a viable means of improving or restoring normoglycemia. Supporting this approach are the studies where treatment of newly onset diabetic NOD mice with an anti-CD3 antibody restored normoglycemia in a substantial portion of mice for a sustained period of time. 72 Very recently, human trials using the same approach also seem quite promising. 73 Although clinical diabetes onset has most often been associated with b-cell death, it is possible that the low levels of insulin production are because of the effects of cytokines that modulate their production. If this is the case, this process can be reversed. [21] [22] [23] [24] [74] [75] [76] Some data strongly suggest that suppression of the activity of the insulitic cells by the induction of immune hyporesponsiveness in clinically diabetic individuals may promote either b-cell neogenesis and/or rescue of the cytokine-suppressed b cells in the insulitic environment. 50, 77, 78 Inherent in this philosophy is the ability to promote TIDM-specific autoantigen tolerance or TIDM-specific autoantigen immune hyporesponsiveness. To acheieve this, one can target genes and/or cells to the thymus, or one can manipulate the peripheral immune effectors using cells alone or gene-engineered cells. These approaches are illustrated in Figure 2 . The evidence suggesting that a preventive approach manipulating the thymic environment of antigen presentation is possible was initially obtained by generating transgenic NOD mice with different H2 (major histocompatibility complex) genes. Mice carrying H2 transgenes conferring resistance did not develop diabetes. [79] [80] [81] [82] [83] Additionally, diabetes in the NOD mouse was also prevented by thymic inoculation of soluble islet antigens in the form of cellular lysates or by expression of putative b-cell autoantigens in the thymus. 79, 84 Could this approach be clinically applicable? Recent data on plasticity of bone marrow stem cells [85] [86] [87] [88] seem to imply that culture conditions could be defined in which bone marrow progenitors could be propagated towards 'thymic' APC. These cells could be engineered using a number of viral or nonviral vector methods (gene vectors to be described in a later section) to present autoantigen. These cells could then be injected into the host where they could eventually populate the recipient thymus. To obviate the problems associated with graft versus host disease in an allogeneic context, one could envisage the use of hematopoietic stem cells propagated from peripheral blood precursors of the recipient. Preliminary evidence seems to suggest that the newly generated insulingenerating cells may not have the same phenotypic makeup of normal b cells and because of this characteristic, they may be able to escape the recurrence of preexisting autoimmunity.
A number of studies have shown that allogeneic bone marrow transplantation into NOD or BB rats with the aim of inducing a state of chimerism can also prevent diabetes and facilitate allo-and xenograft islet transplantation. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] 89 . While the mechanisms are believed to involve central and peripheral chimerism, the applicability of this approach in humans is impeded by the use of very high radiation conditioning of the recipient. The need for complete or partial myeloablative treatment and of allogeneic donors could be obviated by genetically engineering peripheral blood-derived autologous hematopoietic stem cells with transgenes promoting the induction and activity of immunoregulatory networks. Independently of the means utilized to abrogate autoimmunity, a state in which the diabetic patient is free of autoreactive T cells and their assault on pancreatic b cells is optimal to allow or promote the rescue or regeneration of enough insulin-secreting cells in the endogenous pancreas. This may allow physiologic euglycemia. Alternative measures to control the glycemia during the possibly long recovery period must also be implemented.
Case for DC
Although considered as potent immunostimulators, DC have recently been shown to possess tolerogenic characteristics under defined conditions. DC tolerogenicity manifested as the suppression of T-cell activation has been documented in tumor, allo-and autoimmunity. 90 Therapeutics for type I diabetes mellitus R Bottino et al
The conditions that can yield tolerogenic DC include ultraviolet irradiation, as well as exposure to cytotoxic Tlymphocyte antigen-4:immunoglubulin Fc fusion (CTLA-4Ig), transforming growth factor b (TGF-b) or interleukin (IL)-10. [91] [92] [93] How a tolerogenic DC acts to suppress immunoreactivity is not completely understood, but may involve the promotion of anergy of T cells that come into contact with DC, a shift from TH1-to TH2-type responses, apoptosis of the autoreactive T cells or the induction of regulatory cells including regulatory T cells and natural killer-T (NK-T) cells. 90, [94] [95] [96] [97] [98] With the aim of establishing a durable tolerogenic state in the recipient of an allogeneic transplant, myeloid DC have been genetically modified using adenoviral and retroviral vectors encoding CTLA-4Ig, TGF-b and IL-10 in the mouse. [91] [92] [93] . CTLA-4Ig-expressing DC significantly prolong allograft survival, can induce alloantigen-specific Tcell hyporesponsiveness, and display enhanced survival in nonimmunosuppressed, allogeneic hosts. 92 The in vivo presentation of alloantigens by donor or recipient DC in the absence of costimulation along with local production of immunosuppressive molecules like TGF-b, could likely promote the inhibition of antidonor reactivity and promote tolerance induction without causing any major systemic immunosuppression. DC engineered to express vIL-10 following retroviral gene transfer produce high levels of vIL-10 in vitro, exhibit marked reduction in cell surface MHC and costimulatory molecule expression, decrease T-cell allostimulation and promote the induction of T-cell hyporesponsiveness. 91 Genetically engineered DC may be used to prevent islet allograft rejection, since they are able to manipulate antidonor and/or autoantigen immunoreactivity. If recent observations showing islet-specific molecule gene expression in peripheral lymphoid organs can be confirmed in APC 99 like bone marrow-derived DC (Machen et al, unpublished observations), one can envision infusing autologous DC-engineered ex vivo to lack costimulatory capability, but also express islet-specific genes (eg, glutamic acid decarboxylase (GAD)-65 or insulin), into prediabetic or early onset diabetic patients, with the objective of inducing autoantigen-specific hyporesponsiveness. In fact, DC have been treated ex vivo with oligodeoxyribonucleotide decoys to nuclear factor kB (NF-kB), an important maturational transcriptional mediator in DC, and injected into an allogeneic host. These DC were able to prolong the survival of an allogeneic heart. 100 It is likely that this and other transcriptional pathways in APC could be exploited by decoy nucleotide strategies to present autoantigen in the absence of 
Insulin replacement strategies
Novel immunosuppressive cocktails, culture in the presence of homologous serum proteins, minimization of time between pancreas procurement and islet processing combined with transplantation of a larger b-cell mass were the most significant steps in improving islet transplantation outcome in the studies of Shapiro and Co-workers. [101] [102] [103] [104] Although it is not clear which of the parameters contributed most to success, many factors still limit a large-scale diffusion of islet and b-cell replacement for type I diabetic patients. The need for chronic immunosuppression and for multiple donors as a source for islets remain the prime reasons or factors that impose a search for alternative ways of promoting islet cell allograft survival. Tolerogenic protocols, once successful, may allow the use of islet transplantation in young diabetic patients.
Gene transfer technology is such an option and a number of advances have been attained in animal models of islet allograft transplantation. Tables 2a  and 2b lists experiments in which significant prolongation of islet allograft or xenograft survival has been achieved.
The main obstacle for a gene transfer-based approach is the choice of gene transfer vectors. Despite initial enthusiasm about the versatility of adenoviral vectors, their inherent immunogenicity raises a number of serious concerns in view of their possible application to engineer human islets for clinical use. The advent of lentiviral vectors appeared to alleviate some of the immunogenicity concerns, but lentivirus are not as efficient as adenoviruses in transducing intact human islets. As indicated in an earlier section, Table 1a lists a number of gene transfer vectors as well as their pros and cons in the context of gene transfer to intact islets. However, an underappreciated factor that very likely affects the success of islet engraftment is the metabolic status of the islets themselves following isolation and culture. There is no doubt that the time between organ retrieval and islet processing with the inherent intermediate steps including cold storage and enzymatic/ mechanical digestion affects islet yield, viability and function. 30, 105 Furthermore, the culture conditions prior to transplantation can crucially affect islet cells physiology and, consequently, the chance of successful engraftment. In general, the cessation of the oxygen supply to the pancreatic tissue at the time of donor organ harvesting is known to trigger ischemic damage, free-radicalmediated cell degeneration as well as initiation of apoptosis. 106, 107 Also, the separation of the islets from the surrounding matrix and from the neighbor cells driven by the isolation procedure further contributes to activate cell apoptosis. 108, 109 . Immediate-onset ischemia has been proposed to be an important determinant of acute and chronic allograft rejection. 110 In addition, organs carrying contaminating immune and a large number of endothelial cells or in which platelets have been trapped will likely experience a so-called 'cytokines storms', where the onset of apoptototic processes cause an abnormally large release of stored cytokines and other proinflammatory soluble mediators. Moreover, a cycle is initiated whereby cytokines release can exacerbate the formation of reactive oxygen intermediates. 111 Presumably, the combination of all these mechanisms predispose the islets to environmental damage both during culture and at the transplantation site, where inflammation is likely to occur shortly after implant even before alloimmune response starts. Potential approaches to avoid this situation can include the perfusion of the organs with solutions containing chemical inhibitors of apopto- 30, 118, 119 We and others have also shown that the inclusion of synthetic mimetics of free-radical scavengers seem to prevent islet degeneration possibly limiting the initiation of apoptotic processes. 105, 119 Islets also take up oligonucleotides quite efficiently (unpublished observations). Knowledge of the primary transcripts whose protein products are involved in apoptosis activation or suppression of insulin production can be targeted with antisense oligonucleotides during the isolation procedure.
As previously mentioned, oligonucleotide therapy offers a simple and convenient method to interfere with not only gene expression, but also with transcription using short double-stranded decoys containing binding sites for specific transcription factors involved in inflammatory responses, like NF-kB and STATs. Soluble binding proteins and ligand-binding domains of chemokines can also be considered potential tools with which primary islet dysfunction can be prevented. Chemokines are potent immunoattractants fairly resistant to degradation and are sequestered by proteoglycans on the endothelium. 120, 121 Chemokines promote endothelial adhesion in addition to their chemotactic properties. 120, 121 Virally encoded proteins have been identified that bind chemokines and could be a means of achieving chemokine blockade. 122, 123 This blockade can easily be attained using peptide transduction domains fused to recombinant proteins or short oligonucleotides, especially if administered during procurement and reperfusion of the donor pancreas. However, long-term expression of some of these molecules may have a greater effect on graft survival once stable gene expression is achieved. This necessitates the use of gene vectors that can deliver the therapeutic gene with the objective of expression for the entire lifetime of the recipient.
Injection of animals with a number of vectors like adenovirus [124] [125] [126] [127] [128] [129] and adeno-associated virus [130] [131] [132] [133] encoding proinsulin under the control of a number of promoters including CMV, insulin, phosphoenolpyruvate carboxykinase (PEPCK) and L-pyruvate kinase (LPK) has resulted in correction of hyperglycemia. In many instances, however, the effect appears to have been transient. This approach suffers from the potential immunogenicity of the virus, and in many cases precludes a second dosing because of the generation of neutralizing antibodies. Other issues are related to choice of promoter, which in the instance of LPK demonstrates slow kinetics, although one study with this promoter was able to achieve relatively rapid responses to glucose. 131 Finally, many tissues do not express the necessary proteinases that process proinsulin into the potent bioactive insulin.
Surrogate b cells offer an alternative to intact islet transplantation and direct injection of proinsulin-expressing vectors. A variety of cell types including fibroblasts, muscle, neuroendocrine cells and hepatocytes have been engineered to produce insulin. [134] [135] [136] [137] [138] The most notable advances have been made using engineered hepatocytes. 126, 128, 129 Hepatocytes are particularly attractive because they can easily engraft in the liver, and because they possess identical glucose-sensing molecules as the pancreas (eg, GLUT2, glucokinase (GK)). Furthermore, one can exploit a number of hepatocyte gene promoters, which are sensitive to glucose, in order to engineer insulin transgenes to be glucose concentration-sensitive. Despite a number of promising approaches exploiting a number of glucose-regulated promoters, 126, 128, 129, 131, [139] [140] [141] [142] [143] [144] much more work is needed to make hepatocytes into fully surrogate b cells. The first feature that a hepatocyte is missing to properly act like a b-cell surrogate is the ability to respond to glucose in a sufficiently rapid fashion, as rapid as that characteristic of b cells. Second, the liver-specific glucose-sensitive promoters have elements that respond to hormonal and metabolic signals that can impede, attenuate or abrogate the desired objective of tight glucose regulation. For example, instances of hyperglucagonemia, which is to be expected in the absence of functional endogenous b cells in diabetics, will most likely attenuate or repress the LPK promoter as well as other promoters such as GK. 129, 145, 146 Third, glucose-dependent trans-activation of the LPK promoter requires GK-dependent phosphorylation of glucose, an activity that is insulin-dependent. 129 Other promoters have been suggested, such as that of PEPCK, but this promoter is activated by glucagon and inhibited by insulin, which may not result in the desired kinetics of physiological gluco-regulation. 147, 148 It is possible that a combination of promoter elements from different glucose-responive hepatic genes may be needed to create an optimal synthetic promoter to drive hepatic insulin expression in a true glucose-sensitive fashion.
In an entirely different approach, tissue-specific promoters have been exploited to engineer cells to express insulin in cells that are not targets of autoimmune destruction. Lipes et al 149, 150 have expressed insulin in the anterior pituitary gland of NOD mice under the control of the pro-opiomelanocortin promoter. Insulin was expressed, stored into secretory granules and exhibited regulated secretion. Moreover, transplantation of transgenic anterior pituitary tissue to NOD mice was able to restore partially normoglycemia without any signs of immune rejection. 149, 150 It was not clear, however, if in these cells insulin secretion was glucose concentration-dependent. More recently, an ingenious approach harnessing intestinal K cells as surrogate glucose-responsive insulin producers was demonstrated. In this approach, transgenic mice expressing human insulin under the control of the gastrointestinal inhibitory peptide (GIP) promoter were generated. These mice expressed and secreted insulin from intestinal K cells in which the GIP promoter is active. Insulin secretion in these mice was glucose-responsive and was maintained following streptozotocin treatment, indicating that the K cells were spared the effects of streptozotocin. 151 These data suggest that it may be feasible to target the intestinal cells with vectors encoding the GIP-insulin transgene, or by ex vivo engineering intestinal cells in which glucose-sensitive promoters are driving insulin expression. However, an effective means of gene delivery to these cells needs to be developed for in vivo gene therapy, as these cells are present in the crypts of the gut, significantly impeding access to viral transduction.
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Stem/progenitor cells
The considerable genetic manipulations that are required to convert non-b cells into efficient glucose-sensing, insulin-secreting cells have led other investigators into considering means of expanding adult or neonatal b cells or of harnessing the developmental potential of islet precursor cells and embryonal stem cells. However, despite the culture conditions and manipulations, commitment to b cells and insulin production has not always been consistent. [152] [153] [154] [155] [156] [157] Much excitement has also surrounded observations that adult stem cells from bone marrow or from other tissues could 'transdifferentiate' into a number of other lineage-different cell types. Such stem cells have been described and sometimes physically isolated in the nervous system, pancreas, epidermis, mesenchyme, liver, bone, muscle and endothelium. Hematopoietic stem cells, in some studies, were proven able to yield endothelial, brain, muscle, liver and mesenchymal cells. In some studies, hematopoietic cells could also be generated from neuronal or muscle stem cells (reviewed in Wagers et al 88 ) . A number of issues, however, have tempered the enthusiasm with which these observations were initially greeted. The contamination of hematopoietic stem cells with mesenchymal precursors or the programming by growth factors in culture, and more recently, the phenomenon of fusion of stem cells with tissue cells are perhaps the most important variables to better test. 88, 158 Recent developments, however, strengthen the belief that mesenchymal cells in bone marrow may be a multipotent source of cells. [85] [86] [87] This characteristic can be exploited; however, there are no data on whether such cells can be differentiated along the islet and b-cell lineage. Clearly, the ability to manipulate blood-borne progenitors into the b-cell lineage should provide a significant breakthrough for surrogate b-cell technology as insulin replacement.
Despite the current controversy and the serious ethical issues raised by cloning technology, it is likely that therapeutic cloning, under strict and defined conditions, will find its place in stem cell therapies. [159] [160] [161] In this regard, one possible means of propagating b cells or progenitors while avoiding the complications involved with the immune response could entail the removal of DNA or nucleus from somatic cells of a patient, its transfer into an enucleated embryonal stem cell, and its expansion into an appropriate b-cell lineage. While this remains highly speculative at present, the rapid pace of basic work in this area, despite restrictions, will likely yield insight into such manipulations.
Immortalization of islet cells with a b-cell phenotype has been attempted and successfully achieved. Insulin production, however, seems to be linked to terminal differentiation of the cell, an event normally reached with growth arrest. This problem has so far limited the utility of cell immortalization. Also, this approach carries with it the possibility of oncogenic transformation. [162] [163] [164] [165] Although still controversial, there are data indicating that mature human b cells can be induced to replicate under the effects of hepatocyte growth factor (HGF). [166] [167] [168] The limitation of this approach, however, rests on the loss of differentiation of the induced b-cell along with a substantial decrease in insulin production. 169 Conditional replication of non-human b cells has been achieved by placing the SV-40 T antigen under the control of an inducible promoter. 163 In these studies, b cells were able to replicate and to maintain differentiated function under inducible conditions. No data exist on whether such an approach is feasible in human b cells.
Propagation of islet precursor cells with subsequent genetic manipulation to commit them to the b-cell lineage and ultimately to b cells has also been considered. 156, 170 To become feasible, this approach, however, requires a more complete understanding of the hierarchy of master regulatory transcriptional genes. Depending upon the cell type, PDX-1 overexpression can impart onto it a b-cell or a b-cell-like phenotype. 171 [177] [178] [179] [180] [181] , prolactin, 182 placental lactogen, 183, 184 parathyroid hormone-related peptide, 185, 186 and, to a limited extent, TGF-a, 179, 187, 188 can promote pancreatic cell growth and islet cell proliferation. Hart and co-workers 189, 190 colleagues have produced evidence suggesting that fibroblast growth factor (FGF) signalling is important for b-cell generation. 189, 190 Strategies aimed at engineering b-cell progenitors from pancreatic ductular epithelium with FGF in the presence of a permissive PDX-1 expression could promote expansion of b-cell progentors or a differentiation of progenitors into a pre-b-cell lineage.
Another class of factors whose expression and production is associated with pancreatic regeneration has been identified. [191] [192] [193] The Reg-secreted protein, in particular, promotes increases in b-cell mass in rats that had undergone pancreatectomy. [194] [195] [196] The expression and secretion of another molecule that belongs to the Reg family of proteins, termed islet neogenesis-associated protein (INGAP), is upregulated in hamster islets where neogenesis was artificially induced. 197, 198 The precise role of INGAP on b-cell proliferation and function, however, remains unclear.
Very recently, Bonner-Weir et al 199 have shown that it may be feasible to derive b-cell cluster buds from exocrine pancreatic tissue from which originate the ductular epithelial cells destined to become endocrine pancreatic islet cells. This approach is exciting in that mature, nonendocrine tissue of the pancreas need not be wasted during the process of islet isolation, but can be used in defined culture systems to generate islet progenitor cells for further manipulation, genetic or hormonal.
Thus, taken together, the transfer of combinations of genes encoding soluble and intracellular differentiation factors to stem/progenitor cells could become feasible once their precise role in the pathway of commitment and differentiation to b cells becomes clearer. However, b cells have a limited lifespan in vitro. To what extent apoptosis or senescence play a role in this is uncertain. 200, 201 The importance of this breakthrough is underscored by the fact that the major target of xenoreactive antibodies, which promote an acute rejection of porcine tissues, is the epitope that is synthesized by this enzyme. While this is the major porcine xenoantigen, it is almost certain that other minor porcine epitopes will contribute, perhaps not to acute rejection, but to delayed or chronic xenograft rejection and these are challenges that must be surmounted in the future.
Looking towards the future
Clearly, many unexplored avenues await to be negotiated with the technology in existence today. First, combinations of immunosuppressive transgene cassettes should be used to transduce intact islets in culture in parallel with efforts at identifying the vector with the least immunogenicity. Second, it will be impossible to infect every single b-cell within intact islets; consequently, it may be more effective to target soluble molecules that activate b-cell death. In this way, vectors that may not be islet transduction-efficient, yet nonimmunogenic and stably integrating, can still be used effectively when expressing multicistronic transcripts encoding inhibitors of multiple proapoptotic pathways, for example. Cell therapy will very likely include stem and progenitor cells as replacement or surrogate b cells. The biology of these cells is now beginning to be unraveled, and in parallel with advances in tolerance induction and gene transfer technology may yield an efficient means of promoting not only islet allograft or xenograft survival, but may even lead to operational tolerance in an autoimmune background.
